Amgen (AMGN) closed at $318.65, marking a +0.47% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.07%. Elsewhere, the Dow lost 0.62%, while the tech-heavy Nasdaq lost 1 ...

In the latest trading session, Amgen (AMGN) closed at $317.17 ... and the technology-dominated Nasdaq saw an increase of 0.31%. Prior to today's trading, shares of the world's largest biotech ...

Below is Validea's guru fundamental report for AMGEN INC (AMGN). Of the 22 guru strategies we follow, AMGN rates highest using our Multi-Factor Investor model based on the published strategy of ...

Among the largest underlying components of IWY, in trading today Amgen Inc (Symbol: AMGN) is up about 1%, Automatic Data Processing Inc. (Symbol: ADP) is up about 1.2%, and American Tower Corp ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Amgen Inc (Symbol: AMGN), where a total of 19,873 contracts have traded so far ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.

Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...